Microdosing for ADHD: What the Research Shows
ADHD and depression frequently co-occur, and many people with ADHD report that microdosing improves focus, reduces impulsivity, and helps with emotional dysregulation.
The Overlap Between ADHD and Depression
ADHD and depression co-occur at high rates — approximately 50% of adults with ADHD also have a depressive disorder. Both involve dysregulation of the default mode network, difficulty with emotional regulation, and both respond to interventions that promote neuroplasticity.
What the Survey Data Shows
A 2019 survey of 1,116 microdosers found that ADHD was the second most common reason for microdosing (after depression). A 2021 survey specifically examining microdosing for ADHD found that 80% of ADHD microdosers reported improvements in focus and concentration, and 67% reported reduced impulsivity.
The Proposed Mechanism
The default mode network (DMN) is overactive in both ADHD and depression. In ADHD, this manifests as mind-wandering, difficulty sustaining attention, and intrusive thoughts. Psilocybin reduces DMN rigidity, which may explain why it helps with both conditions.
Microdosing and ADHD Medication
There are no documented dangerous interactions between psilocybin at microdosing doses and stimulant medications. However, both affect serotonin and dopamine systems, and the combination can feel overstimulating for some people. Starting on a day when you're not taking stimulants is a reasonable approach.
This article is for informational purposes only and does not constitute medical advice.
This article is for informational purposes only and does not constitute medical advice. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult your physician before making any changes to your health regimen.